89bio, a San Francisco-based biopharmaceutical company, focuses on therapies for liver and cardio-metabolic diseases, with its lead candidate, pegozafermin, targeting nonalcoholic steatohepatitis and severe hypertriglyceridemia. The company went public on November 11, 2019, and employs 70 people.
Charles Mcwherter bought 5,000 shares of ETNB on 21 January at $6.55 per share, worth a total of $33K. They now own 15,000 ETNB shares, or a 50% holding increase.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
